A new GLP-1 pill helped patients lose up to 8% of their body weight in a major trial.
Eli Lilly developed the drug, called orforglipron, to treat type 2 diabetes.
Researchers compared it with oral semaglutide in a year-long phase 3 study.
More than 1,500 adults from several countries took part.
Patients who received orforglipron lost more weight than those on semaglutide.
They also achieved better blood sugar control.
Unlike semaglutide tablets, patients can take orforglipron without fasting.
This feature may improve convenience and adherence.
However, more participants stopped orforglipron بسبب stomach-related side effects.
Regulators in the US and Europe have not yet approved the drug.
Experts believe effective oral options could expand access to treatment.
They argue that easier therapies may improve long-term weight and diabetes control.
